Navigation Links
EMA Starts Formal Review of Glybera(R) Dossier
Date:1/25/2010

pectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
2. AMT Starts Preregistration Trial for Glybera(TM)
3. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
4. BioCis Pharma Starts Phase IIa Trial in Psoriasis
5. The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum
6. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
11. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Reed Technology and Information Services ... management, preparation, and submission to the U.S. Food and ... new Lot Distribution Report (LDR) service for manufacturers of ... with the FDA’s new rule on electronic submission of ... the volume and timing of particular biologics introduced to ...
(Date:4/17/2015)... , April 17, 2015  Guggenheim Securities, the investment ... announced the hiring of William Tanner as ... Mr. Tanner will start work at Guggenheim in ... office. "Bill brings a wealth ... to our experienced and highly acclaimed healthcare team," said ...
(Date:4/17/2015)... 2015 LC Sciences LLC, a ... today that it is seeking beta testers for ... PCR based targeted sequencing technology. The system offers ... enables accurate detection of rare variants. It utilizes ... The company will collaborate with beta testers to ...
(Date:4/16/2015)... KYOTO and OSAKA, Japan ... iPS Cell Research Application (CiRA) of Kyoto University ... that they will work together to develop clinical ... such as heart failure, diabetes mellitus, neurological disorders ... iPS Cell Applications" (T-CiRA) is designed to expedite ...
Breaking Biology Technology:Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3
... tools and find the organisms to break down the ... the key step toward fermentation of those sugars ... and economically efficient before cellulosic biofuels can compete with ... any exploration of systems that involve largely unknown processes, ...
... Inc. (Nasdaq: ONTY ) will conduct a conference call to discuss its ... 4:30 p.m. Eastern time ( 1:30 p.m. Pacific time ). , ... To participate in the call by telephone, ... addition, the call will be webcast live and can be accessed on the ...
... CHICAGO , July 26 Advanced ... Board: ADLS), a biopharmaceutical company engaged in the discovery, ... areas of infection, oncology and respiratory diseases, today announced ... and option agreement with The University of British ...
Cached Biology Technology:New hydrolysis model promising tool in cellulosic biofuel studies 2New hydrolysis model promising tool in cellulosic biofuel studies 3Advanced Life Sciences Expands Antibiotic Pipeline 2Advanced Life Sciences Expands Antibiotic Pipeline 3Advanced Life Sciences Expands Antibiotic Pipeline 4
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... SPRING HARBOR, N.Y. (Jan. 11, 2011) -- The ... a decade ago, has revolutionized biological research. But ... and linking basic biological processes to genomic information can ... new resource that provides easy access to information about ...
... One of the challenges of gene therapy - a set ... or RNA) - is to assure that this material arrives ... substantial amount along the way and without producing any undesired ... use of different types of vectors, molecules capable of transporting ...
... microscope, a coronavirus may resemble a spiny sea urchin or ... takes its name). Previously recognized as the second leading ... important diseases in many domesticated animals, a new disease form ... when the SARS coronavirus (CoV) surfaced in Asia. The ...
Cached Biology News:New user-friendly resource connects human genes to biological functions 2Nanodisk gene therapy 2New research aims to shut down viral assembly line 2New research aims to shut down viral assembly line 3New research aims to shut down viral assembly line 4New research aims to shut down viral assembly line 5
... Recognizes K+ Cl- Cotransporter-1 ... no significant sequence homology ... CCC.,SPECIES REACTIVITIES: The immunogen ... in human, mouse, porcine ...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
KOR-1 (C-20)...
Biology Products: